secwatch.observer — SEC 8-K summary
======================================

Issuer:     aTYR PHARMA INC (ATYR)
CIK:        0001339970
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0001339970-25-000007
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

aTyr completes Phase 3 EFZO-FIT last patient visit; topline data mid-September 2025
--------------------------------------------------------------------------------

- Last patient visit completed in Phase 3 EFZO-FIT study of efzofitimod in pulmonary sarcoidosis; topline data expected mid-September 2025.
- Cash, equivalents and investments were $83.2M at June 30, 2025; raised ~$30.7M from ATM offering post-quarter.
- R&D expenses $15.4M, G&A $4.9M for Q2 2025.
- Interim Phase 2 EFZO-CONNECT data in SSc-ILD showed stable/improved mRSS in efzofitimod-treated patients (n=8).
- Advanced ATYR0101 to IND candidate for pulmonary fibrosis; IND filing expected H2 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1339970/000133997025000007/0001339970-25-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1339970/000133997025000007/atyr-20250807.htm
  HTML page:      https://secwatch.observer/filing/0001339970-25-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer